
CRL Stock Forecast & Price Target
CRL Analyst Ratings
Bulls say
Charles River is supported by a strengthening demand backdrop, highlighted by a solid Q3 beat and raise and a 5th consecutive quarter of improving leading indicators, including a 1.09x B2B in DSA that supports expectations for MSD growth in 2027. Its positive outlook also rests on margin expansion levers from pricing power, cost reductions, and divestitures, with management pointing to 5%-7% organic growth and more meaningful improvement in operating margins as pricing from RFPs flows through in 2H27. Manufacturing adds further support, as CRL lifted expectations to MSD organic growth with a higher-margin, post-CDMO portfolio, while NAMs and AI appear more complementary than disruptive, expanding CRL’s role in preclinical and bioanalysis workflows.
Bears say
Charles River is vulnerable to weaker biopharma demand for pre-clinical safety and IND-enabling studies, which could leave growth across RMS, DSA, and Manufacturing below the recovery thesis and pressure operating leverage. The outlook is also burdened by execution risk in the K.F. (Cambodia) vertical integration, where the expected $16M in 2026 and $39M in 2027 EPS accretion and 120 bps of margin uplift could be reduced by cost inflation, supply-chain issues, or lower NHP utilization. In addition, accelerating FDA acceptance of organ-on-chip, organoid, and in silico methods could erode traditional animal-study volumes, especially in DSA, where CRL has only about $120M of NAMs revenue and minimal safety exposure.
This aggregate rating is based on analysts' research of Charles River Laboratories and is not a guaranteed prediction by Public.com or investment advice.
CRL Analyst Forecast & Price Prediction
Start investing in CRL
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Charles River Laboratories (CRL) Forecast
CRL Analyst Forecast & Price Prediction
Start investing in CRL
Order type
Buy in
Order amount
Est. shares
0 shares